OSIS

OSIS is mislabeled by SIC as a semiconductor name but the 10-K MD&A makes clear it is a vertically integrated specialty systems business with three segments: Security (70% of FY2025 revenue), Optoelectronics & Manufacturing (20%), and Healthcare (10%). That mix — homeland security screening, defense/aerospace electronics, and hospital patient monitoring — is structurally less cyclical than the semis bucket implies, and FY2025 delivered $1.71B revenue (+11.3% YoY), operating income of $217.5M (+15% per MD&A), and diluted EPS of $8.71 (+18%). Growth is accelerating off a multi-year base ($1.15B → $1.18B → $1.28B → $1.54B → $1.71B), with net income compounding from $91.8M in FY2023 to $150M in FY2025 — operating leverage is real and net margin is expanding even as R&D rose 12.5% to $73.4M, signaling reinvestment rather than cost cuts driving the beat.

Valuation is reasonable rather than stretched: 24.5x trailing EPS and 2.1x sales for a business growing the top line ~11% and the bottom line ~17% is a sub-1.5 PEG on earnings growth, and ROE of 15.7% on a $951M equity base is solid for a manufacturer. The standout flag is balance-sheet shift: long-term debt jumped 258% to $464M and total liabilities rose 20.3% versus equity up only 10.1%, lifting liabilities/equity to 1.36x. MD&A attributes part of FY2025 to two tuck-in acquisitions (and two more in FY2024), so the leverage looks deal-funded, not distress — and operating cash flow tripled to $97.6M, with management spending $80.4M on buybacks, both signs that the cash engine and capital return remain intact.